"The makers of the immune-modulating-drug Ampligen, Hemispherx Biopharma Inc., presented new data Sept. 8 at the first International Workshop on XMRV suggesting that the drug works differently in chronic fatigue syndrome patients depending on their XMRV status."
Read more: Ampligen for XMRV-Positive Chronic Fatigue Syndrome:
No comments:
Post a Comment